{
  "first_published_at": "2011-02-10", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON108678", 
  "title": "Daptomycin: risk of eosinophilic pneumonia", 
  "tags": "{\"parsed_therapeutic\": [\"infectious-disease\"], \"Audience:\": [\"Secondary care\"], \"Therapeutic area:\": [\"Infectious disease\"]}", 
  "_document_number": 163, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "infectious-disease"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Daptomycin: risk of eosinophilic pneumonia</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: February 2011</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!---->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<div id=\"dsuSynopsis\" class=\"yellow\">\r\n\t\t\t\t\t\t\t\t\t<div class=\"dsuArticlePadding\">\r\n\t\t\t\t\t\t\t\t\t<span id=\"dsuSynopsisTitle\"><b>Summary</b></span>\t\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<br>There have been rare but potentially serious reports of eosinophilic pneumonia associated with daptomycin (Cubicin&#9660;). If eosinophilic pneumonia is suspected, daptomycin should be discontinued immediately and if appropriate the patient treated with corticosteroids. Daptomycin should not be readministered to patients who have experienced eosinophilic pneumonia with this drug<br>\t\r\n\t\t\t\t\t\t\t\t\t</div>         \t\t\r\n\t\t\t\t\t\t\t\t\t<div id=\"dsuSynopsisCut\">\r\n\t\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Daptomycin (Cubicin&#9660;) is indicated for the treatment of complicated skin and soft-tissue infections; right-sided infective endocarditis due to <em>Staphylococcus aureus</em>; and <em>S aureus</em> bacteraemia when associated with right-sided infective endocarditis or with complicated skin and soft-tissue infections.</p><h2>Risk of eosinophilic pneumonia</h2><p>Since daptomycin was licensed in 2006, there have been case reports globally of eosinophilic pneumonia and pulmonary eosinophilia associated with its use. Although the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate is very low (&lt;1/10 000). In severe cases, hypoxic respiratory insufficiency requiring mechanical ventilation may occur, making prompt recognition of the clinical syndrome critical.</p><h2>Clinical presentation</h2><p>The most common symptoms of eosinophilic pneumonia include cough, fever, and dyspnoea. Diagnostic findings include increased eosinophils in the lung tissue or bronchoalveolar lavage fluid, along with diffuse infiltrates on chest radiographs. Although clinical suspicion should be raised if there is an elevated peripheral eosinophil count in the setting of pulmonary infiltrates, there have been cases of eosinophilic pneumonia with normal peripheral eosinophil counts.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>The most common symptoms of eosinophilic pneumonia include cough, fever, and dyspnoea (see above for further diagnostic criteria). Most cases have occurred after 2 weeks of treatment</li>\r\n\t\t\t\t<li>Healthcare professionals should react promptly to signs of eosinophilic pneumonia with daptomycin treatment. Daptomycin should be discontinued immediately and if appropriate the patient treated with corticosteroids</li>\r\n\t\t\t\t<li>Daptomycin should not be readministered to patients who have experienced eosinophilic pneumonia with this drug</li>\r\n\t\t\t\t<li>Report suspected adverse reactions with daptomycin through the Yellow Card Scheme&mdash;see <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates</li>\r\n\t\t\t</ul></div><p><strong>Further information:</strong></p><p>See <a href=\"ssLINK/CON106073\">letter for healthcare professionals sent January 2011</a></p><p>BNF section 5.1.7 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/129714.htm\" target=\"_blank\">Some other antibacterials</a></p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Feb 2011, vol 4 issue 7: A2.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Daptomycin (Cubicin&#9660;) is indicated for the treatment of complicated skin and soft-tissue infections; right-sided infective endocarditis due to <em>Staphylococcus aureus</em>; and <em>S aureus</em> bacteraemia when associated with right-sided infective endocarditis or with complicated skin and soft-tissue infections.</p><h2>Risk of eosinophilic pneumonia</h2><p>Since daptomycin was licensed in 2006, there have been case reports globally of eosinophilic pneumonia and pulmonary eosinophilia associated with its use. Although the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate is very low (&lt;1/10 000). In severe cases, hypoxic respiratory insufficiency requiring mechanical ventilation may occur, making prompt recognition of the clinical syndrome critical.</p><h2>Clinical presentation</h2><p>The most common symptoms of eosinophilic pneumonia include cough, fever, and dyspnoea. Diagnostic findings include increased eosinophils in the lung tissue or bronchoalveolar lavage fluid, along with diffuse infiltrates on chest radiographs. Although clinical suspicion should be raised if there is an elevated peripheral eosinophil count in the setting of pulmonary infiltrates, there have been cases of eosinophilic pneumonia with normal peripheral eosinophil counts.</p><div class=\"dull_highlight\">\r\n\t\t\t<p><strong>Advice for healthcare professionals:</strong></p>\r\n\t\t\t<ul>\r\n\t\t\t\t<li>The most common symptoms of eosinophilic pneumonia include cough, fever, and dyspnoea (see above for further diagnostic criteria). Most cases have occurred after 2 weeks of treatment</li>\r\n\t\t\t\t<li>Healthcare professionals should react promptly to signs of eosinophilic pneumonia with daptomycin treatment. Daptomycin should be discontinued immediately and if appropriate the patient treated with corticosteroids</li>\r\n\t\t\t\t<li>Daptomycin should not be readministered to patients who have experienced eosinophilic pneumonia with this drug</li>\r\n\t\t\t\t<li>Report suspected adverse reactions with daptomycin through the Yellow Card Scheme&#8212;see <a href=\"http://www.yellowcard.gov.uk/\">www.yellowcard.gov.uk</a>. When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates</li>\r\n\t\t\t</ul></div><p><strong>Further information:</strong></p><p>See <a href=\"http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON106073\">letter for healthcare professionals sent January 2011</a></p><p>BNF section 5.1.7 <a href=\"http://www.medicinescomplete.com/mc/bnf/current/129714.htm\" target=\"_blank\">Some other antibacterials</a></p><p>&#160;</p><p><em>Article citation: Drug Safety Update Feb 2011, vol 4 issue 7: A2.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2011-02-01", 
  "date_last_modified": "2011-02-09", 
  "_assets": [], 
  "_item_id": 163, 
  "summary": "There have been rare but potentially serious reports of eosinophilic pneumonia associated with daptomycin (Cubicin▼). If eosinophilic pneumonia is suspected, daptomycin should be discontinued immediately and if appropriate the patient treated with corticosteroids. Daptomycin should not be readministered to patients who have experienced eosinophilic pneumonia with this drug", 
  "body": "Article date: February 2011\n\nDaptomycin (Cubicin▼) is indicated for the treatment of complicated skin and soft-tissue infections; right-sided infective endocarditis due to Staphylococcus aureus; and S aureus bacteraemia when associated with right-sided infective endocarditis or with complicated skin and soft-tissue infections.\n\n## Risk of eosinophilic pneumonia\n\nSince daptomycin was licensed in 2006, there have been case reports globally of eosinophilic pneumonia and pulmonary eosinophilia associated with its use. Although the exact incidence of eosinophilic pneumonia associated with daptomycin is unknown, to date the reporting rate is very low (<1/10 000). In severe cases, hypoxic respiratory insufficiency requiring mechanical ventilation may occur, making prompt recognition of the clinical syndrome critical.\n\n## Clinical presentation\n\nThe most common symptoms of eosinophilic pneumonia include cough, fever, and dyspnoea. Diagnostic findings include increased eosinophils in the lung tissue or bronchoalveolar lavage fluid, along with diffuse infiltrates on chest radiographs. Although clinical suspicion should be raised if there is an elevated peripheral eosinophil count in the setting of pulmonary infiltrates, there have been cases of eosinophilic pneumonia with normal peripheral eosinophil counts.\n\nAdvice for healthcare professionals:  \n  \n  * The most common symptoms of eosinophilic pneumonia include cough, fever, and dyspnoea (see above for further diagnostic criteria). Most cases have occurred after 2 weeks of treatment  \n  * Healthcare professionals should react promptly to signs of eosinophilic pneumonia with daptomycin treatment. Daptomycin should be discontinued immediately and if appropriate the patient treated with corticosteroids  \n  * Daptomycin should not be readministered to patients who have experienced eosinophilic pneumonia with this drug  \n  * Report suspected adverse reactions with daptomycin through the Yellow Card Scheme—see [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk/). When reporting please provide as much information as possible, including information about medical history, any concomitant medication, onset, and treatment dates  \n  \nFurther information:\n\nSee [letter for healthcare professionals sent January 2011](http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/ssLINK/CON106073)\n\nBNF section 5.1.7 [Some other antibacterials](http://www.medicinescomplete.com/mc/bnf/current/129714.htm)\n\n \n\nArticle citation: Drug Safety Update Feb 2011, vol 4 issue 7: A2.\n"
}